To study the effects of an externally applied negative abdominal pressure device designed to lower the effects of intra-abdominal pressure (IAP) on headaches and pulsatile tinnitus in severely obese women with pseudotumor cerebri (PTC). DESIGN: Short-term clinical intervention trial in the Clinical Research Center. Days 1 and 3 were`control' days; on days 2 and 4 ± 6 patients were in the device from 8:00 am to noon and from 1:00 to 5:00 pm, and on nights 7 ± 11 they were in the device from 10:00 pm to 8:00 am. The last four patients were treated in a device with a counter-traction mechanism. SUBJECTS: Seven centrally obese women with PTC. MEASUREMENTS: Headache and pulsatile tinnitus severity were graded by the patient using visual analog scale (1 ± 10) and averaged for the time that the device was in use or not in use. IAP was estimated from urinary bladder pressure (UBP) before and during device use. The internal jugular vein (IJV) elliptical cross-sectional area was measured with B-mode ultrasonography; the timed average velocity was measured by Doppler. RESULTS: There was a decrease in both headache (6.8 AE 0.8 to 4.2 AE 0.8, P`0.05) and pulsatile tinnitus (4.2 AE 0.5 to 1.8 AE 0.5, P`0.02) within 5 min, and in headache (to 2.2 AE 0.8, P`0.01) and tinnitus (to 1.7 AE 0.5, P`0.01) within 1 h of device activation. UBP decreased (P`0.001) from 19.1 AE 3 to 12.5 AE 2.8 cmH 2 O. Headache remained improved throughout time that the device was used. During the second week, ®ve of seven patients slept in the device without dif®culty and four awoke without headache. There was a progressive decrease (P`0.01) in headache during the day after sleeping in the device at night as compared with days 1 and 3 when it was not used (6.5 AE 0.5, day 1; 4.1 AE 0.7, day 3; 3.1 AE 0.8, day 8; 2.3 AE 0.8, day 10). Headaches returned late in the afternoon in two patients; the device was reactivated and headache again improved. Five patients underwent IJV sonography; the IJV area decreased (129 AE 53 to 100 AE 44 mm 2 , P 0.06) without a change in IJV¯ow (1004 AE 802 to 1000 AE 589 mlamin) with the device. When activated, the device was pulled into the patient, creating discomfort that was alleviated with the counter-traction mechanism in the last four patients. One patient developed a 5 cm area of blisters that resolved when the device was worn over a hospital gown. CONCLUSIONS: Decreasing IAP relieved headaches and pulsatile tinnitus in PTC. When patients slept in the device, they awoke without headache or tinnitus, which remained markedly improved throughout most of the following day. This study supports the hypothesis that PTC in obese women is secondary to an increased IAP.
Introduction
In a previous study we documented a signi®cant decrease in intracranial pressure (ICP) in severely obese patients with pseudotumor cerebri (PTC) following gastric surgery-induced weight loss. 1 We also noted markedly increased cardiac ®lling pressures in another group of morbidly obese patients with obesity hypoventilation syndrome. 2 These pressures were higher than in most patients in congestive heart failure, yet these patients were not in heart failure. The cardiac ®lling pressures returned to normal following surgically induced weight loss. In another study we found urinary bladder pressures (UBP) in severely obese women with stress over¯ow urinary incontinence to be markedly elevated Ð higher than in patients with an acute abdominal compartment syndrome, who require emergency abdominal decompression because of acute pulmonary and renal failure. 3 Thus, the hypothesis was developed that increased intraabdominal pressure (IAP) produces an increased pleural pressure that raises central venous pressure (CVP) and increases intracranial pressure (ICP) in obese patients with PTC. Other studies have supported this hypothesis. In an acute porcine study we reported that raising IAP increased pleural pressure and ICP and these returned to normal following abdominal decompression. 4 When a median sternotomy and pleuropericardiotomy was performed, preventing the increase in pleural pressure, the ICP did not rise with an increased IAP. 5 In another study severely obese PTC patients were found to have an increased sagittal abdominal diameter (a re¯ection of central obesity), IAP, trans-esophageal pleural pressure, CVP and ICP at the time of gastric bypass surgery. 6 Severely obese patients have an increased UBP, re¯ecting an increased IAP. 7 The increased IAP is associated with a number of obesity co-morbidities including PTC, gastroesophageal re¯ux, obesity hypoventilation, stress over¯ow urinary incontinence, incisional hemia, venous stasis ulcers and systemic hypertension. These obese patients are considered to have a chronic abdominal compartment syndrome. We hypothesized that application of an externally applied negative abdominal pressure device would decrease the IAP and correct the obesity co-morbidity, including PTC. We further hypothesized that using the device at night would lead to decreased symptoms during the following day.
Methods
Seven severely obese women (BMI ! 35 kgam 2 ) with PTC scheduled for gastric bypass were asked to participate in the study. Patients met the modi®ed Dandy criteria for PTC. The CSF pressures were obtained from their referring neurologist or neuro-opthalmologist 2 ± 4 months prior to entry in to the study. Cerebral imaging studies were supportive of the diagnosis of PTC in all patients: ®ve had a negative cerebral magnetic resonance imaging (MRI) study; two had a negative cerebral computerized axial tomographic (CAT) scan; three had both studies which were negative and one had a negative magnetic resonance cerebral angiogram (MRA). All patients complained of persistent, severe headaches on the ®rst control day of the study. All patients were examined by a neuro-ophthalmologist (WLF) prior to entry into the study for the presence of papilledema and visual ®eld defects and none of the patients had papilledema immediately prior to the study. However, two patients had papilledema when initially diagnosed. One of these patients had a lumboperitoneal shunt placed prior to the study without relief of her headache or pulsatile tinnitus. Her CSF pressure was measured through the shunt immediately before the study and was still elevated at 220 mmH 2 O.
The study was approved by the Committee on the Conduct of Human Research at the Medical College of Virginia of Virginia Commonwealth University and an Investigative Device Exemption (IDE) was provided by the Food and Drug Administration (FDA). All patients signed an informed consent document after the nature of the study had been fully explained. Three days prior to admission to the General Clinical Research Center (CRC) at the Medical College of Virginia Hospitals, they were asked to discontinue medications used for the treatment of their PTC but were allowed to continue the use of pain medications prior to admission but not thereafter. Days 1 and 3 were`control' days and days 2 and 4 ± 6 were`device' days when they were in the ABSHELL 2 from 8:00 am to noon and from 1:00 to 5:00 pm. During the second week, ®ve of the seven patients slept in the device from 10:00 pm to 8:00 am. The ®rst three patients were treated in a device consisting of a customdesigned ®berglass shell with a foam rubber skirt at the skin ± shell interface, a connecting tubing and a vacuum pump ( Figure 1 ). The negative pressure applied was measured at the shell through a small polyvinyl tubing which was attached to the main vacuum tubing and connected to a pressure gage on the pump. Two vacuum pumps were used in this study: the NEV 100, a negative pressure ventilator put on Although activation of this device provided a signi®cant decrease in UBP and improvement in headache and pulsatile tinnitus, the shell was pulled into the patient, causing discomfort in the lower chest and pelvic areas. The addition of a device providing 16 kg of counter-traction using the gradual application of weights through a pulley system permitted a further reduction in UBP and relief of the discomfort with the device (Figure 2 ). Counter-traction could be provided in a vertical or horizontal direction so Negative abdominal pressure for pesudotumor HJ Sugerman et al that the patient was able to lie in either a supine or lateral decubitus position. The severity of headache and pulsatile tinnitus was assessed using a visual analog scale queried by the CRC nurse for which 1 equaled no headache or tinnitus and 10 equaled the most severe headache or tinnitus the patient had experienced. These data were recorded before and at 5 min and 1, 2 and 4 h with ABSHELL 2 activation during the day and upon awakening and every 4 h during the day after sleeping in the device. Urinary bladder pressure (UBP), a surrogate for abdominal pressure, was measured according to the following technique. A Foley catheter was inserted into the bladder using sterile technique. The catheterized bladder was allowed to empty; a water manometer with a three-way stopcock was then connected to the bladder catheter with an 18 gage needle inserted into the rubber gasket on the urinary drainage bag tubing. The drainage tubing was clamped and 50 ml of saline was inserted into the bladder by adjusting the stopcock. The water manometer was opened to the urinary bladder and zeroed to the urethral meatus. The UBP was recorded at end-expiration in cmH 2 O.
Respiratory oscillations of the¯uid in the water manometer were noted prior to all measurements. UBP measurements were obtained every hour on days 1 (control day) and 2 (device day) and averaged for the time the device was in use or not in use. The urinary bladder catheter was then removed. Internal jugular vein (IJV) cross-sectional area (horizontal Â vertical Â 3.14a4) was measured with B-mode ultrasonography in ®ve patients. Timed average velocity (TAV) was measured in four patients by pulsed Doppler and ow calculated from TAV Â area. These measurements were obtained before and during use of the ABSHELL 2 . Data were analyzed using paired Student's t-test and ANOVA with Donnett's t-test comparing baseline with subsequent days of treatment as appropriate. As the principal investigator is a co-owner of the ABSHELL 2 device, the data were independently reviewed by the Clinical Research Center Scienti®c Advisory Committee to assure validity.
Results
The mean CSF pressure was 329 AE 92 mmH 2 O. There was a decrease (P`0.001) in both headache and pulsatile tinnitus within 5 min of device activation (Table 1) . UBP decreased from 19.1 AE 3 to 12.5 AE 2.8 cmH 2 O with use of the device. Headache remained improved throughout the time the device was used. During the second week, ®ve of the seven patients slept in the device without dif®culty. One patient found the ABSHELL 2 too uncomfortable to sleep in prior to the development of the counter-traction and one patient's surgery was scheduled at the end of the ®rst week of study so she did not sleep in the device. Four of the ®ve awoke without any headache or pulsatile tinnitus. There was a progressive decrease (P`0.01) in headache when averaged for the day after sleeping in the device as compared to headache severity on days 1 and 3 when the ABSHELL 2 was not used (Table 2) . Headaches returned late in the afternoon in two patients. They requested device reactivation and again had relief of headache. There was a trend (P 0.06)
Figure 2 Patient in ABSHELL
2 device with counter-traction mechanism with patient rotated partially to the right. The tubing is seen from the ABSHELL 2 to the vacuum pump on the¯oor by the patient's bed. (Table 3) . When activated the device was pulled into the patient, creating discomfort, which was alleviated with the counter-traction mechanism in the last four patients. Two patients developed mild erythema and one patient a 5 cm area of blisters at the shell ± skin interface, which resolved when the device was worn over a hospital gown.
Discussion
Previous studies have suggested that central obesity and increased intra-abdominal pressure are signi®cant contributing factors to the pathophysiology of PTC. 1 ± 7 There are studies which support the concept that PTC is secondary to venous engorgement rather than to excessive production or decreased absorption of CSF. 8 ± 10 The results of this study provide further support to this hypothesis. It is hypothesized that the ABSHELL 2 device works by decreasing intraabdominal pressure, which causes reduced intra-pleural pressure, leading to decreased central venous and jugular venous pressures and producing a decreased cerebral vascular pressure. The ultrasonographic results reported in this paper support this hypothesis. However, the decrease in IJV area did not quite reach statistical signi®cance, possibly due to a type II statistical error. We do not believe the device works by producing increased egress of either cerebral venous blood from the brain or cerebrospinal¯uid from the cerebral ventricles. The device produces less positive intra-abdominal pressure, rather than a negative intra-abdominal pressure. Previous acute porcine studies with an increased intraabdominal pressure have documented an immediate decrease in directly measured intra-abdominal, intrapleural, central venous and intracranial pressures with application of continuous negative abdominal pressure (CNAP 2 ). 11 We tried to measure CSF pressures in several of these patients prior to, during or following application of this device; however, the data appeared to be inaccurate as the pressures did not oscillate with respirations. In a previous case report, we noted a marked decrease in directly measured ventriculostomy ICP pressure in a head injury patient with an acute abdominal compartment syndrome following surgical abdominal decompression, permitting removal of the ventriculostomy which was being used to drain CSF¯uid to maintain an ICP 20 mmHg. 12 In another acute porcine study in an animal with an increased intra-abdominal pressure in which the ICP was raised with an intracerebral balloon, application of CNAP 2 immediately decreased ICP and improved cerebral perfusion pressure. 13 It has been hypothesized that severe central obesity leads to increased intra-abdominal pressure and the development of a chronic abdominal compartment syndrome which may responsible for multiple obesity-related co-morbidity problems in addition to PTC. 7 These would include venous stasis ulcers, obesity hypoventilation syndrome, gastroesophageal re¯ux, and probable systemic hypertension. The device was developed to evaluate the effectiveness of lowering intra-abdominal pressure in severely obese patients with these conditions. It has also been hypothesized that pre-eclampsia and eclampsia are secondary to a subacute increase in intra-abdominal pressure. We recently have received FDA approval for a feasibility trial to study the device in pre-eclampsia; this trial will be initiated shortly.
Two concerns regarding the hypothesis that increased intra-abdominal pressure and raised intra-pleural pressure is the cause of PTC are: (1) why don't all severely obese women develop PTC; and (2) why is PTC rarely seen in centrally obese men? Many women have peripheral obesity, rather than central obesity, and they would not be expected to have an increased intra-abdominal pressure. It is possible that the increased intra-abdominal pressure is not transmitted to the chest as often in men as it is in women or that, if the pressure is transmitted, there may be more competent valves at the origin of the IJV in men than in women, preventing the transmission of this pressure to the IJV and sagittal sinus veins. The effect on cerebral venous engorgement may be ampli®ed by female sexual hormones, leading to an increased frequency of PTC in centrally obese women as compared to men.
Previous studies 1, 14 have documented the ef®cacy of gastric surgery-induced weight loss for the treatment of PTC associated with severe obesity. Furthermore, additional obesity co-morbidity is often seen in these patients, including type II diabetes, obstructive sleep apnea, infertility, dysmenorrhea, stress over¯ow urinary incontinence, as well as the previously mentioned co-morbidities associated with an increased intra-abdominal pressure. These also respond to surgically induced weight loss.
Ventriculoperitoneal and lumboperitoneal shunts have a high rate of failure in patients with PTC, 15 probably as a result of shunting from one high-pressure system (the CSF) to another high-pressure system (the abdomen). For severely obese patients with PTC that have failed to respond to medical treatment, gastric bypass for obesity is the procedure of choice for the long-term management of their obesityrelated comorbidities and increased ICP. Each of the seven patients in this study has had a signi®cant weight loss following their gastric bypass procedure with complete relief of their headaches and pulsatile tinnitus within 3 months of the surgery. The ABSHELL 2 may provide a nonsurgical alternative in these patients for symptomatic relief of headache and pulsatile tinnitus. Further randomized, Negative abdominal pressure for pesudotumor HJ Sugerman et al prospective trials validating the safety and ef®cacy for the long-term treatment of PTC will be required before it can be clinically available.
